Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Endonovo Therapeutics's Enterprise Value is $6.99 Mil.
Endonovo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $0.08 Mil. Therefore, Endonovo Therapeutics's EV-to-OCF for today is 90.73.
The historical rank and industry rank for Endonovo Therapeutics's EV-to-OCF or its related term are showing as below:
ENDV'
s EV-to-OCF Range Over the Past 10 Years
Min: -52.97 Med: -9.86 Max: 91.91
Current: 90.73
During the past 13 years, the highest EV-to-OCF of Endonovo Therapeutics was 91.91. The lowest was -52.97. And the median was -9.86.
ENDV's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.45
vs ENDV: 90.73
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Endonovo Therapeutics's PE Ratio (TTM) for today is calculated as:
Endonovo Therapeutics's share price for today is $5.0E-5.
Endonovo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Endonovo Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Endonovo Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Endonovo Therapeutics's EV-to-OCF falls into.
Endonovo Therapeutics's current Enterprise Value is $6.99 Mil.
Endonovo Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Endonovo Therapeutics (ENDV) has a EV-to-OCF of 90.73 as of Aug. 09, 2026.
Is Endonovo Therapeutics' EV-to-OCF too high?
Endonovo Therapeutics' current EV-to-OCF is 90.73.
How does Endonovo Therapeutics' EV-to-OCF compare to RGBP and SIGY?
Endonovo Therapeutics' EV-to-OCF of 90.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Endonovo Therapeutics's current EV-to-OCF is 90.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current EV-to-OCF of 90.73. The current EV-to-OCF is 90.73. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current EV-to-OCF is 90.73 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENDV has been successfully added to your 
